Intentional Wellness MD Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A recognizable medication name is not the same thing as evidence for a particular treatment service. Intentional Wellness MD advertises semaglutide, tirzepatide and a GLP-1 Microdose program through a concierge telehealth model. The useful question is not simply whether these names appear in medical research. It is what the platform documents about the actual formulation, prescribing relationship, pharmacy, follow-up and financial arrangement a patient would receive—and how far that documentation supports its marketing.

Public pages consulted October 19, 2026, provide meaningful detail about enrollment, compounded medication, home delivery and recurring billing. They also present different legal entities, different cancellation deadlines and privacy statements with different scopes. This documentary review separates advertised services from independently established clinical evidence. It does not verify professional licenses, test medication quality or establish treatment outcomes, and it treats unresolved details as questions rather than proof that a service is unavailable.

At a glance

Documented programs: Intentional Wellness MD advertises semaglutide, tirzepatide and GLP-1 Microdose; the semaglutide page specifies an injectable route.
Sources: [12] [6] [7]
Prescribing responsibility: The platform says independent licensed practitioners make clinical and prescription decisions; the platform itself does not practice medicine, prescribe or dispense.
Sources: [13]
Pricing and renewal: Flat-rate pricing is advertised without a concrete dollar amount in the consulted text. Recurring monthly orders are charged immediately and every 30 days under the terms.
Sources: [12] [10]
Cancellation discrepancy: The footer requires 30 days’ notice for membership cancellation; the terms allow subscription cancellation at least 48 hours before monthly processing through auto-refill settings.
Sources: [13] [10]
Compounded medication: The program includes compounded medication. The provider acknowledges that compounded medications are not FDA approved.
Sources: [12] [13]

Start with the service, not the medication headline

Intentional Wellness MD describes itself as a concierge platform connecting patients with independent clinical providers and state-licensed compounding pharmacies. Its disclaimer explicitly separates those roles: the platform does not practice medicine, write prescriptions or dispense pharmaceuticals. Although some marketing uses “physician-directed,” other passages refer more broadly to licensed clinicians. The documentation does not identify the treating professionals, independent medical group or dispensing pharmacies by name, so those relationships cannot be independently assessed here.

The business identity also needs clarification. The About page lists Intentional Wellness MD, LLC, at 614 E. Sipapu Dr., Gilbert, Arizona 85297. Terms last updated June 1, 2026, instead identify Ohana Health & Wealth, LLC as the website’s owner and operator. The consulted documents do not explain the corporate relationship. This difference does not establish misconduct, but a prospective patient should know which entity collects payment, administers the account and responds to contractual questions.

The business extends beyond GLP-1 care. It advertises clinician-reviewed peptides compounded in a U.S. pharmacy and in-person stem-cell therapy for patients across the Phoenix valley. Those listings describe additional offerings, not evidence supporting the GLP-1 programs. The stem-cell page directs readers to contact the team without documenting the procedure, product or price. More generally, public provider documents establish what is represented, not everything that is delivered.

Sources: [8] [10] [13] [5]

Three program names, different levels of product detail

The semaglutide page describes a weekly injection, licensed-clinician supervision, home delivery and flat-rate pricing. The tirzepatide page advertises a dual GLP-1/GIP agonist program under physician direction, also at a flat rate. However, the consulted tirzepatide text does not explicitly establish its route. Neither medication name alone identifies the exact preparation a patient would receive. The program’s inclusion of compounded medication makes the prescription’s formulation and presentation especially important details to obtain.

GLP-1 Microdose is positioned differently: the provider markets it for body composition, metabolic health and longevity rather than aggressive weight loss. It names people near their goal weight and those who poorly tolerated standard GLP-1 treatment as possible candidates, while directing people with significant weight to lose toward a standard protocol. These are the provider’s positioning statements, not demonstrated benefits. The consulted text does not identify Microdose’s active ingredient or administration route.

Navigation also mentions Oral GLP-1s, but the reviewed documentation does not establish that program’s medicines, formulations or terms. A menu label should not be treated as a complete product listing. The distinctions below show why formulation and route require separate evidence questions, rather than assuming every service using a familiar ingredient name matches a studied treatment.

What the advertised program names do—and do not—establish
Program or claim	Documented description	Remaining evidence question
Semaglutide	Weekly injection with clinician supervision	Exact compounded formulation and presentation
Tirzepatide	Dual GLP-1/GIP program with flat-rate pricing	Route and exact preparation are not established
GLP-1 Microdose	Lower-dose program marketed for body composition and longevity	Active ingredient, route and program-specific benefit evidence
Oral GLP-1s navigation	A navigation reference	Medicine, formulation and program conditions
Compounded medication inclusion	Medication prepared by partner compounding pharmacies	Named pharmacy and prescription-specific product details

Sources: [12] [6] [7] [3] [4]

Research on a drug is not a performance report for this platform

The clinical context includes STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide, but neither was a study of Intentional Wellness MD or its compounded products. Results from those trials cannot establish this platform’s outcomes, validate Microdose longevity claims or predict an individual’s response. Nor should trial percentages be used to rank providers. The central distinction is straightforward: a clinical trial is not a telehealth company performance report.

The provider acknowledges that compounded medications are not FDA approved and that FDA has not independently verified their safety, efficacy and quality. FDA approval applies to a specific product, not to a clinic or pharmacy. Conversely, nonapproval alone does not demonstrate clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy; that recommendation is not a blanket judgment about this platform.

The claim that partner pharmacies are FDA-regulated and state-licensed does not resolve product-level questions. Four certificate PDFs available for this review did not yield readable clinical content, so they could not establish a testing laboratory, results, purity or sterility. This is a verification limitation, not a finding of failed testing. A patient can request readable, product-relevant documentation, while recognizing that approved products and compounded preparations raise distinct evidence questions.

Sources: [13] [1] [3] [4]

Enrollment promises still require an individual clinical decision

The advertised intake begins with a comprehensive digital health history and coordination of diagnostic testing. The homepage specifically requires laboratory work for TRT/HRT and advanced longevity protocols; it does not establish a universal GLP-1 laboratory requirement. A licensed provider is described as reviewing biomarkers, history and goals to design a plan. Under the terms, obtaining a prescription product requires a consultation, a finding that the product is appropriate and an issued prescription. Enrollment does not guarantee approval.

The semaglutide and tirzepatide pages advertise candidates aged 18 or older with BMI of at least 27, or at least 25 with weight-related conditions. These are provider-advertised criteria, not universal medication eligibility rules. NIDDK’s general adult pharmacotherapy thresholds are different: BMI of at least 30, or at least 27 with weight-related health problems. Neither set of thresholds substitutes for individualized assessment. The terms additionally require the local age of majority if it exceeds 18.

The semaglutide page lists exclusions including personal or family history of medullary thyroid carcinoma or MEN 2, pregnancy, breastfeeding or planning pregnancy, active pancreatitis and untreated severe gastrointestinal disease. Tirzepatide marketing also addresses patients who have plateaued on a single-agonist GLP-1 and seek a supervised change. Those statements should become consultation topics, not self-screening instructions. The documents do not specify the initial consultation format or establish Spanish-language care, interpretation or other language-access arrangements.

Sources: [13] [10] [12] [6] [2]

Follow-up and geographic reach need operational detail

Intentional Wellness MD advertises telehealth across all 50 states through a national provider network. Its terms qualify that reach: availability depends on state-specific regulations and can change, and patients must be physically in the same state as their account’s shipping address during consultation. A national coverage claim therefore is not confirmation that every program is currently available to every applicant. Travelers and people using an address in another state should clarify the location requirement before arranging care.

The semaglutide page promises assignment to a dedicated provider licensed in the patient’s state rather than repeated handoffs between call centers. It also advertises direct messaging with the provider and care team between scheduled check-ins, alongside structured reviews calibrated to response. Those are useful descriptions of intended continuity. However, the public documentation does not establish a fixed GLP-1 follow-up frequency, clinical message response deadline or detailed process for urgent medication concerns.

The contact page lists support@intentionalwellnessmd.com and 1-480-433-8584, with clinical hours Monday through Friday, 9 a.m. to 5 p.m. Arizona MST. Its form promises a team response within 24 hours. That is a contact-response claim, not a deadline for clinical approval, medication preparation or delivery. NIDDK describes follow-up as attention to tolerability and response, not merely renewed payment; prospective patients should ask how this platform turns its messaging and check-in promises into scheduled clinical care.

Sources: [12] [10] [9] [2]

Pharmacy choice and delivery carry separate responsibilities

The advertised flat-rate program includes compounded medication prepared by partner pharmacies and shipped on a structured cadence. The terms restrict fulfillment to a pharmacy accessible through the platform and require purchasers to waive choosing another pharmacy for that purchase. Patients who want an existing local pharmacy should resolve that restriction before buying. Because the consulted pages do not name the dispensing partners, they also do not establish which pharmacy would handle a particular patient’s prescription or product questions.

Home delivery is described as temperature-controlled, discreet and unmarked. Those are packaging claims, not proof of an uninterrupted cold chain for every shipment. The documents do not establish preparation, dispatch or arrival deadlines, identify the carrier or describe a temperature-excursion resolution process. FDA explicitly recommends not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. A promised delivery feature does not override that advice.

The terms also state that prescription products will not be dispensed in child-resistant containers. That is a material home-storage consideration, separate from whether outer packaging is discreet. Before shipment, useful questions include who supplies handling instructions, whom to contact about a damaged or warm package, and how replacement decisions are made. FDA has received reports of compounded-medication measurement and administration errors; instructions should be clarified with the prescriber or pharmacist rather than reconstructed from an online review.

Sources: [12] [10] [1]

Flat-rate language leaves the actual transaction unresolved

The semaglutide page advertises no hidden fees, no consultation charges and no dose-change surcharges, but the consulted text supplies no concrete price. The terms describe certain prescription subscriptions as a bundle containing pharmacy medication fees, medical-group service fees and platform access. An included clinical fee can coexist with no separately billed consultation charge, but the documentation does not provide the actual breakdown. Lab costs, materials, insurance acceptance and HSA/FSA arrangements also remain unestablished.

For recurring monthly orders, the terms authorize an immediate charge and another every 30 days until cancellation, with electronic notice five to seven days before a scheduled transaction. Thirty days is the documented interval, not a calendar-month guarantee. Neither that interval nor a shipping cadence establishes medication quantity per payment or a minimum commitment. The homepage also advertises price matching without documenting requirements or exclusions in the consulted passage, so its practical value cannot be assessed.

Cancellation is the sharper unresolved issue. The footer requires 30 days’ notice before a membership’s next billing cycle; the terms allow subscription cancellation by disabling auto-refill at least 48 hours before monthly processing. These may concern different arrangements, but the documents do not explain their interaction. The footer says treatment charges are not processed without medical approval and otherwise makes consultations, memberships, visits and fulfilled prescriptions nonrefundable once services begin or medication is processed. Cancellation therefore should not be assumed to produce a refund.

Sources: [12] [13] [10]

Privacy claims require reading beyond the FAQ

The semaglutide FAQ says the platform is HIPAA compliant, limits medical-information sharing to the assigned provider and dispensing pharmacy, and never sells or shares data. The terms use a more qualified description: Ohana Health & Wealth, LLC is not a HIPAA covered entity and may act as a business associate of a pharmacy or medical group in certain circumstances. These statements concern different roles and scopes; the broad FAQ language should not replace the more detailed disclosures.

The California notice adds another distinction. It says certain personal information may be made available to third parties for advertising measurement, improvement and relevant offers, and those disclosures may count as a sale or sharing under California law. That does not establish that medical records are sold. It does mean a reader cannot safely interpret the FAQ’s broad wording as proof that no categories of personal data reach advertising partners.

The practical evidence request is specific: ask which entity receives intake information, which privacy notice covers clinical records, what information is used for advertising, and what choices apply. Likewise, obtain written clarification of the operator’s identity and the applicable cancellation rule. These documentation gaps do not erase the platform’s described clinical process, but they limit how confidently a patient can understand the full relationship before submitting health information or agreeing to recurring charges.

Sources: [12] [10] [11] [13]

Questions & answers

Does Intentional Wellness MD document FDA-approved medication in its flat-rate program?

The advertised inclusion is compounded medication, and the provider acknowledges that compounded medications are not FDA approved. The consulted documents do not establish a specific FDA-approved branded product as the program’s supplied medicine. Ask for the exact prescription, formulation, route, presentation and dispensing pharmacy. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug; the clinician should explain the individual rationale.

Sources: [12] [13] [1]

What will the first payment and renewals cost?

No concrete dollar amount appears in the consulted pricing text. The provider advertises a flat rate without consultation charges or dose-change surcharges. For recurring monthly orders, the terms authorize immediate billing and charges every 30 days. Request the actual quote, medication quantity, included services, possible laboratory or materials costs, and the point at which nonrefundable services begin before authorizing payment.

Sources: [12] [10] [13]

Is GLP-1 Microdose supported by the same evidence as standard treatment?

That is not established by the consulted documentation. Intentional Wellness MD markets Microdose for body composition, metabolic health and longevity, including people near goal weight, but does not identify its active ingredient or route in the reviewed text. STEP 1 and SURMOUNT-1 do not establish outcomes for this program, its compounded preparation or its longevity claims. Ask what evidence supports the exact proposed protocol and intended benefit.

Sources: [7] [3] [4]

Can I take the prescription to my preferred pharmacy?

The terms say a prescription included in a purchase will be filled through a pharmacy accessible through the platform and require waiving pharmacy choice for that purchase. They advise against purchasing if you do not accept that restriction. The consulted pages do not identify the dispensing partners by name, so request that information and the relevant pharmacy contact before deciding whether the arrangement suits you.

Sources: [10]

Which cancellation deadline should I rely on?

The documents do not resolve that question. The footer specifies 30 days’ notice for memberships, while the terms permit subscription cancellation through auto-refill settings at least 48 hours before monthly processing. Ask whether both arrangements apply to your enrollment and obtain written confirmation of the effective cancellation date and any remaining charge. Do not assume stopping future renewals reverses charges already incurred.

Sources: [13] [10]

How can I confirm availability and reach the team?

The platform advertises all-state telehealth, but its terms make availability subject to state rules and require your physical location to match the shipping-address state during consultation. Contact support@intentionalwellnessmd.com or 1-480-433-8584 to confirm the specific program. Listed clinical hours are weekdays, 9 a.m.–5 p.m. Arizona MST. The contact form’s 24-hour response promise is not a prescription-approval or medication-arrival deadline.

Sources: [12] [10] [9]

Our assessment

Intentional Wellness MD documents a recognizable telehealth pathway: clinical intake, independent prescribing, partner-pharmacy fulfillment, home delivery and ongoing messaging. Its acknowledgment of compounded medication’s regulatory status is useful, as are the stated pharmacy-channel and geographic restrictions. What remains unestablished is equally consequential: exact prices and preparations, named care partners, provider-specific outcomes, and how conflicting cancellation and privacy statements apply to an individual account. The sensible next step is a written, program-specific explanation of those details—not an assumption that familiar medication names validate every advertised benefit or that documentation gaps prove poor care.

Visit Intentional Wellness MD’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Intentional Wellness MD Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the service, not the medication headline

02Three program names, different levels of product detail

03Research on a drug is not a performance report for this platform

04Enrollment promises still require an individual clinical decision

05Follow-up and geographic reach need operational detail

06Pharmacy choice and delivery carry separate responsibilities

07Flat-rate language leaves the actual transaction unresolved

08Privacy claims require reading beyond the FAQ